C Day
C Day
Verified email at ncl.ac.uk
Title
Cited by
Cited by
Year
Steatohepatitis: a tale of two “hits”?
CP Day, OFW James
Gastroenterology 114 (4), 842-845, 1998
53061998
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
24412007
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.
CP Day, JM McComb, RW Campbell
Heart 63 (6), 342-344, 1990
19641990
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
G Targher, CP Day, E Bonora
New England Journal of Medicine 363 (14), 1341-1350, 2010
19052010
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
GP Aithal, CP Day, PJL Kesteven, AK Daly
The Lancet 353 (9154), 717-719, 1999
15981999
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
QM Anstee, G Targher, CP Day
Nature reviews Gastroenterology & hepatology 10 (6), 330-344, 2013
13522013
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
G Targher, L Bertolini, R Padovani, S Rodella, R Tessari, L Zenari, C Day, ...
Diabetes care 30 (5), 1212-1218, 2007
12472007
The natural history of nonalcoholic fatty liver: a follow‐up study
MR Teli, OFW James, AD Burt, MK Bennett, CP Day
Hepatology 22 (6), 1714-1719, 1995
11651995
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of The Liver, ...
Obesity facts 9 (2), 65-90, 2016
10272016
HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816-819, 2009
10072009
Non-alcoholic fatty liver disease: the mist gradually clears
NMW de Alwis, CP Day
Journal of hepatology 48, S104-S112, 2008
9522008
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management
S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee
Journal of hepatology 62 (5), 1148-1155, 2015
8292015
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ...
Hepatology 47 (2), 455-460, 2008
7672008
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
S McPherson, SF Stewart, E Henderson, AD Burt, CP Day
Gut 59 (9), 1265-1269, 2010
6752010
Pathogenesis of steatohepatitis
CP Day
Best practice & research Clinical gastroenterology 16 (5), 663-678, 2002
6652002
Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis
AM Diehl, C Day
N Engl J Med 377, 2063-2072, 2017
6082017
EASL clinical practical guidelines: management of alcoholic liver disease
European Association For The Study Of The Liver
Journal of hepatology 57 (2), 399-420, 2012
5902012
Prednisolone or pentoxifylline for alcoholic hepatitis
MR Thursz, P Richardson, M Allison, A Austin, M Bowers, CP Day, ...
New England Journal of Medicine 372 (17), 1619-1628, 2015
5632015
Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease
L Valenti, A Al‐Serri, AK Daly, E Galmozzi, R Rametta, P Dongiovanni, ...
Hepatology 51 (4), 1209-1217, 2010
5612010
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ...
Journal of hepatology 69 (4), 896-904, 2018
5582018
The system can't perform the operation now. Try again later.
Articles 1–20